glp-1 and afib Impact of Receptor Agonist Therapy on Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients: A Real-World Data Analysis HRS 2026: GLP-1 Receptor Agonists

Weight loss itself reduces blood pressure

Side effects and perceived lack of efficacy (no results perceived) each accounted for 8% of discontinuations

What can it help change

The skin should be healthy and clear of lumps, bumps, or scars

Evolv is now running a 90-day human study with 120 participants to measure weight, appetite, and HbA1C outcomes

The symptoms often follow a pattern where: Many patients report improvement in nausea and malaise after the first few weeks Symptoms often become more manageable or resolve completely with continued treatment Some patients may experience mild symptoms that persist longer, though these typically become less bothersome over time Factors affecting duration: Several variables influence how long symptoms persist: Dose escalation schedule slower titration (gradual dose increases) typically results in fewer and shorter-lasting symptoms Individual sensitivity some patients are more susceptible to gastrointestinal side effects Concurrent medications other drugs affecting the GI tract may prolong symptoms Dietary habits eating patterns and food choices can influence symptom severity and duration It is worth noting that symptoms may temporarily recur when the dose is increased according to the recommended schedule (which varies by product weekly for liraglutide, every 4 weeks for weekly semaglutide), but subsequent episodes are often less severe than the initial experience